XSHE
300595
Market cap1.35bUSD
Oct 09, Last price
10.31CNY
1D
2.49%
1Q
-3.73%
IPO
-11.43%
Name
Autek China Inc
Chart & performance
P/E
19.25
P/S
4.99
EPS
0.54
Div yield, %
2.78%
Shrs. gr., 5y
1.07%
Rev. gr., 5y
16.27%
Revenues
1.85b
+2.00%
Net income
480m
-16.20%
CFO
827m
+20.80%
Dividend
May 20, 20260.132 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Autek China Inc. focuses its operations on the entire process from conceptualization and development to the manufacturing and distribution of products related to ocular health and visual care. The company's offerings prominently feature specialized ophthalmic medical devices, including orthokeratology lenses, which are utilized for improving eyesight and managing the progression of short-sightedness. This enterprise was founded in 2001 and is primarily based in Hefei, China.
Key people
Yuequn Tao
Chairman of the Board, General Manager · since 2013
Guoxin Dong
Deputy General Manager, Director of Professional Affairs Management Center · since 2024
Zhiying Fu
Deputy General Manager, Chief R&D Officer, Director · since 2020
Yongzhan Xiao
Deputy General Manager · since 2021
Zhe Zhu
Deputy General Manager, Director of Anhui Business Center · since 2024
Yongjian Sun
Deputy Chief Operating Officer
Chun Wang
Chief Production Officer
Xianmei Shi
Chief Operating Officer, Deputy General Manager, Secretary of the Board, Director · since 2019
Yihua Cheng
Deputy Director of Anhui Business Center, Director · since 2024
Tongge Huang
Director · since 2013
Lizhi Wei
Chief Financial Officer, Director · since 2021
Minsong Tang
Independent Director · since 2020
Qiang Xu
Independent Director · since 2023
Independent Director · since 2020
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||